Floatz Rating
BB68/100
Confidence
Indicative
Sponsor
Tanta University
Modality
Small molecule
Development Phase
Phase 4 / Approved
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
74High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07084753CT.gov Non-opioid Anesthesia Based on Thoracic Paravertebral Block During Laparoscopic Sleeve Gastrectomy | — | Not Yet Recruiting | — | — | — |
NCT06125665CT.gov Aminophylline on Perioperative Lung Mechanics in COPD Morbidly Obese Patients Undergoing Laparoscopic Bariatric Surgery | — | Unknown | — | — | — |
NCT06714981CT.gov Hemodynamics Stability During Opioid Free Anesthesia for Patients with Obesity | — | Completed | — | — | — |
NCT04525274CT.gov Intraperitoneal Dexmedetomidine Versus Ketamine With Bupivacaine For Postoperative Analgesia | — | Completed | — | — | — |
NCT04730375CT.gov Evaluation of the Effect of Different Doses Dexmedetomidine Infusion on Lung Mechanics and Oxygenation in Obese Patients | — | Completed | — | — | — |
NCT04436731CT.gov Sex Disparities in Hypoxic Sympatholysis and Impact of Obesity | — | Active Not Recruiting | — | — | — |
NCT04260659CT.gov Opioid Free vs Opioid Based Anesthesia for Laparoscopic Sleeve Gastrectomy | — | Completed | — | — | — |
NCT03756961CT.gov Effects of an Opioid Free/Sparing Care Pathway for Patients Undergoing Obesity Surgery | — | Recruiting | — | — | — |
NCT02880540CT.gov Dexmedetomidine to Treat Bariatric Surgery-associated Pain | — | Completed | — | — | — |
NCT02557867CT.gov The Effect of Obesity in Dexmedetomidine Metabolic Clearance | — | Unknown | — | — | — |
Show 4 more trialsShow fewer
NCT02213159CT.gov Dexmedetomidine for Postoperative Analgesia After Bariatric Surgery | — | Completed | — | — | — |
NCT03029715CT.gov Anaesthesia for Laparoscopic Sleeve Gastrectomy | — | Completed | — | — | — |
NCT01864187CT.gov Pharmacokinetics of Dexmedetomidine in Morbid Obesity | — | Unknown | — | — | — |
NCT02187068CT.gov Dexmedetomidine Pharmacokinetics in the Obese | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
59High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Obesity Disorder
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Dexmedetomidine (this asset) | Tanta University | Approved | BB · 68 |
| vi-0521 | VIVUS LLC | P4 | BBB |
| Tirzepatide | Royal North Shore Hospital | P4 | BBB |
| asc30 | Ascletis Pharma (China) Co., Limited | P2 | BBB |
| Phentermine | Russell McCulloh, MD | P4 | BBB |
| Survodutide | Boehringer Ingelheim | P3 | BBB |
| Deoxycholic Acid | University of California, San Diego | P4 | BBB |
| Efsubaglutide Alfa | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | P4 | BBB |
| Cagrilintide | Novo Nordisk A/S | P3 | BBB |
+42 more in the Obesity Disorder cohort
Other indications for Dexmedetomidine
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Schizophreniform Disorder | — | P4 | A · 80 |
| Schizoaffective Disorder | — | P4 | BBB · 77 |
| Neuralgia | — | P4 | BBB · 76 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Dexmedetomidine in Obesity Disorder. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/dexmedetomidine-obesity-disorder
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →